Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.98 USD | +1.09% | +7.56% | +0.81% |
03:31pm | Celldex Therapeutics Launches Phase 3 Trials for Barzolvolimab in Patients With Chronic Skin Inflammation | MT |
06-18 | Stifel Initiates Celldex Therapeutics at Buy Rating With $58 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.81% | 2.61B | |
+25.83% | 46.56B | |
+45.38% | 41.67B | |
+0.69% | 41.16B | |
+30.52% | 32.4B | |
+22.30% | 28.18B | |
-6.35% | 28.1B | |
+49.25% | 14.52B | |
+49.18% | 13.74B | |
+3.45% | 12.17B |
- Stock Market
- Equities
- CLDX Stock
- News Celldex Therapeutics, Inc.
- Guggenheim Adjusts Price Target on Celldex Therapeutics to $63 From $68, Maintains Buy Rating